AstraZeneca leukaemia drug meets trial end-point

6th Jun 2019 08:34

(Sharecast News) - AstraZeneca said on Thursday its Calquence leukaemia drug had met the primary endpoint of a phase 3 trial and would allow it to file for regulatory approval later this year.It said the drug showed meaningful improvement in patients with lymphocytic leukaemia when compared with a chemotherapy-based combination treatment.Calquence in May met a primary endpoint early in a separate trial last month, AstraZeneca said in a statement.AstraZeneca executive vice-president of oncology research and development José Baselga said the results from both trials "will serve as the foundation for regulatory submissions later this year".